Alzheimer's drugs market forecast to expand at 7.5% CAGR to 2025
Allergan (NYSE: AGN) and Swiss pharma giant Novartis (NOVN: VX) dominated the global Alzheimer's disease drugs market in 2016, their global market presence attributable to acquisitions of leading emerging brands.
Other key players in the global Alzheimer's drugs market include Eisai (TYO: 4523), Lundbeck (LUND: CO), Daiichi Sankyo (TYO: 4568), Ono Pharmaceutical (TYO: 4528), Merz GmbH, and Johnson & Johnson (NYSE: JNJ).
The wide scope for the Alzheimer's drugs market in emerging regions, due to lack of awareness about the disease in several underdeveloped countries, has made these regions crucial for global Alzheimer's drugs market players. However, players located in developed regions such as North America and Europe are likely to lead the global Alzheimer's drugs market in the coming years due to the widespread availability of Alzheimer's treatment channels in countries such as the USA, Canada, the UK and Germany.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze